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ABBREVIATIONS AND SI-UNITS 
 
ACT   Autologous Chondrocyte Transplantation 
AGC   Aggrecan 
cDNA  complementary Deoxyribonucleic Acid 
Col 1  Collagen 1 
Col 2  Collagen 2 
COMP  Cartilage Oligomeric Matrix Protein 
CO2  Carbon Dioxide 
ECM   Extracellular Matrix 
ELISA  Enzyme-Linked ImmunoSorbent Assay  
FBS  Fetal Bovine Serum 
GAG  Glycosaminoglycan 
HA   Hydroxyapatite 
HE  Hematoxylin Eosin  
H2O2  Hydrogen peroxide 
ITS   Insulin Transferrin Selenium 
mRNA  messenger RiboNucleic Acid 
MSC  Mesenchymal Stem Cell 
OA  Osteoarthritis 
OAT  Osteochondral Autologous Transplant 
PCR  Polymerase Chain Reaction 
pH  negative logarithm to the base of 10 of the hydrogen ion concentration 
PMMA  Polymethylmethacrylate 
6  
 
ROM   Range of Motion 
qPCR  quantitative Polymerase Chain Reaction 
rpm  revolutions per minute 
TBS  Tris-Buffered Saline 
SEM  Standard Error of the Mean 
SD  Standard Deviation 
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SI Units 
g    gram    
G    gravitational constant (6.674×10−11 N⋅m2/kg2) 
Gy    Gray (J/kg) 
Hz    Hertz (s-1) 
M    Molar mass (g/mol) 
m    meter   
min    minute 
ml    millilitre   
N    Newton (kg⋅m/s2) 
s    second 
°C    degree Celsius 
  
8  
 
1 ABSTRACT 
Background: Numerous techniques and treatments have been developed to prevent 
joint cartilage from degenerating or to restore its properties. One of these is 
MaioRegen® (MR) -a cell-free hybrid scaffold consisting of 3 collagen 1 layers with 
increasing hydroxyapatite content from the top cartilage to the bottom bone layer-, 
which demonstrated very promising results in clinical studies.  
Material and Methods: A novel model was developed for the investigation of MR’s 
behavior in an in vitro setting. Ring-shaped osteochondral cylinders (outer diameter 8 
mm; inner diameter 6 mm) were prepared from fresh bovine knee joints using 
standardized punches (Arthrex®). Osteochondral autologous transplants (OATs; 
positive control) or MR scaffolds with a diameter of 6 mm were then inserted into the 
osteochondral rings and cultured for periods of up to 10 weeks. Histological (HE, 
Safranin-O, and aggrecan immunohistology), transcriptional (collagen 1, 2, aggrecan, 
and COMP), biochemical (DMB assay, ELISA for collagen 1, 2 and aggrecan), and 
biomechanical analyses were performed at the start, as well as after 4, 8 and 10 weeks 
of in vitro culture. 
Results: The culture system remained stable without signs of cell death or necrosis for 
any tissue component throughout 10 weeks of cell culture. In the OAT group, 
fibrocartilaginous tissue formation in the osseous part and a complete bridging of the 
gap between the osseous and transplant was observed after 8 weeks. Despite 
substantial cell migration into the scaffold, local proteoglycan deposition and significant 
increases in aggrecan gene expression, in contrast, the MR scaffold progressively 
dissolved and thus showed decreased biomechanical resistances over time.  
Conclusion: The novel model appears suitable for high-throughput investigation of 
osteochondral regeneration in vitro. The OAT group represents a suitable control for 
future studies based on its efficient tissue integration in vitro and the similarity of its in 
vitro and clinical performance. Due to its rapid degradation in vitro and in vivo, the MR 
scaffold may show limitations in the present in vitro model and in the clinical context of 
osteochondral regeneration. 
9  
 
2 INTRODUCTION 
2.1 Hyaline cartilage 
Articular cartilage found in synovial- hydrated joints is called hyaline cartilage. This 
type of cartilage shows a special stratified structure and molecular arrangement of the 
extra-cellular matrix (ECM), which is crucial for its smooth and physiological joint 
function. 
2.2 Structure of hyaline cartilage 
Hyaline cartilage consists of up to 80% of water. The typical cells of this tissue are 
chondrocytes, which are present as isolated cells or in multi-cellular chondrones. As 
cartilage is a bradytrophic tissue, chondrocytes have an anaerobic metabolism (Poole 
1997). Supply with oxygen is therefore mainly based on diffusion. This is supported by 
natural biomechanical pressure that pushes oxygenated synovial fluid into the cartilage 
(Muir 1995).  
The ECM between these cells is highly organized and shows a typical orientation of 
the collagen fibers (Fig.1). As a result, the cartilage can be subdivided into four layers. 
 
Figure 1: Principal structure of hyaline cartilage, shown by un-blinding the orientation of the collagen fibers and 
by visualizing shape and distribution of the chondrocytes in the different layers.(Gross 2009) 
2.2.1 Surface (tangential) layer 
This layer (also known as lamina splendens) represents the part of the cartilage that is 
closest to the joint space and shows a thickness of 100-300 µm only. Chondrocytes in 
this layer are flat and spindle-shaped (Poole 1997). In this layer, the concentration of 
collagen is the highest and cross-linked collagen fibers run parallel to the joint surface. 
The latter is the reason for the high tensile strength of this layer, which protects the 
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cartilage from erosive damage through shear forces and tangential stretching (Broom 
und Marra 1985). 
2.2.2 Transitional (oblique) layer 
The transitional layer is just beneath the surface layer and above the radiate layer. It 
shows a high elasticity and accounts for 20 to 70% of the cartilage thickness. From the 
top to the bottom, the orientation of the cells changes from a tangential to a vertical 
orientation with respect to the cartilage surface, thus following the changing direction 
of the collagen fibers (Broom und Marra 1985).  Biochemically, this layer is 
characterized by an increasing concentration of proteoglycans and a decreasing 
relative concentration of collagen (Poole 1997). Functionally, this results in decreased 
tensile strength and increased pressure loading capacity. 
2.2.3 Radiate (vertical) layer 
The radiate layer (also radiate stratum) is situated between the transitional layer and 
the calcified layer. A clearly detectable edge, called tidemark, is found between the 
radiate layer and the calcified layer. In this layer, all chondrocytes and collagen fibers 
are orientated vertically to the cartilage surface and are organized in column-like 
structures. In this area, the relative concentration of proteoglycans is the highest, while 
the relative quantity of collagen is decreasing. The maximal concentration of 
proteoglycans is found at 50 to 70% depth of the overall thickness. This results in a 
maximal pressure loading capacity of the cartilage in this section (Roth und Mow 1980). 
2.2.4 Calcified cartilage 
This fourth layer of the cartilage is localized just above the sub-chondral bone (Brighton 
et al. 1984). In this layer chondrocytes aggregate in small groups, are round-shaped 
and surrounded by non-calcified lacunae. The special feature of this layer is its ability 
to regenerate after damage. Although this layer accounts for only 3-9% of the overall 
thickness of the cartilage, it plays an important role as a potential therapeutic target 
(Wakitani et al. 1994). At the same time, there is some evidence that progenitor cells 
that reside in the superficial layer can also contribute to cartilage regeneration 
(Mesallati et al. 2015). 
2.2.5 Extracellular-matrix (ECM) 
The ECM of the hyaline cartilage consists of a framework of collagen fibers and the 
space between the collagen fibers. More than 90% of the collagen fibers consist of 
collagen type 2, while collagen 1 accounts only for a minor fraction of approximately 
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10%. The collagen fibers of this framework are organized in parallel and antiparallel 
fibers (Hedlund et al. 1993). The space between the collagen fibers consists of water, 
minerals, glycoproteins, and proteoglycans. The most characteristic proteoglycan of 
hyaline cartilage is the large chondroitin sulfate molecule aggrecan. As a typical 
proteoglycan, it has a high water binding capacity and is therefore one of the most 
important proteins for establishing the pressure loading capacity of the joint cartilage 
(Ulrich-Vinther et al. 2003). 
Proteoglycans and collagen fibers build a network with electrostatic interactions, again 
supporting the enormous pressure loading capacity and tensile strength of hyaline 
cartilage. 
2.3 Functions of hyaline cartilage 
There are regionally diverse processes in the cartilage, since proteoglycans have the 
tendency to accumulate water, whereas collagen fibers limit the expansion of the 
aggrecan molecules (Shakibaei et al. 2008). These two characteristics are crucial for 
the pressure loading capacity and the tensile strength of the cartilage. If strain is 
applied to the cartilage, liquid is pressed out of the cartilaginous tissue and reabsorbed 
during relaxation. The expelled lubricin-enriched liquid mingles with synovial fluid and 
contributes to a reduced friction coefficient. Therefore, healthy joints are considered 
almost frictionless (Jay und Waller 2014). 
In the case of joint pathology, a low concentration of proteoglycans and a subsequently 
reduced swelling leads to an irregular distribution of the mechanical strain. As a 
consequence, the subchondral bone is more heavily loaded and the cartilage tissue 
will degenerate.  
The opposite effect is observed when defects in the collagen framework lead to a 
decreased hydrostatic pressure, which results in cartilage edema due to over-
absorption of water by proteoglycans (Shakibaei et al. 2008). This complex, balanced 
system is thus a target of various pathologies, inevitably resulting in the destruction of 
articular cartilage. 
2.4 Acute and traumatic damage 
Trauma-derived cartilage damage has a higher incidence among young, sportive and 
active individuals. Thus, most of the damage results in overstraining peak loads or 
accidents especially among elite athletes. However, individuals having an insufficient 
musculature incapable of attenuating the forces of the musculoskeletal system are at 
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high risk, too. Limited traumatic cartilage damage is not necessarily associated with a 
loss of cartilage substance and the physiological function of the chondrocytes may 
remain unimpaired (Buckwalter 1997). Thus, the endogenous regeneration of the 
cartilage clearly depends on the size and depth of the damage (Fig. 2). There are 
several different types of defects. 
1. Chondral defects. In this case, only cartilaginous tissue is affected and the 
cartilage is either partially or completely damaged. However, the subchondral bone 
does not show any lesion. In cases of chondral defects with a diameter of less than 2 
mm, endogenous regeneration should be considered as a satisfactory treatment option 
(Konig und Kirschner 2003). 
2. Osteochondral defects. If the full thickness of cartilage and also the 
subchondral bone are simultaneously damaged, the resulting defect is called an 
osteochondral defect. As there is no border between bone marrow and cartilage 
anymore, mesenchymal stem cells (MSC) migrate into the defect and attempt to 
synthesize novel ECM. However, this ECM shows completely different properties than 
the cartilaginous ECM, as it contains less proteoglycans and collagen 2, which results 
in decreased pressure loading capacity and tensile strength. In addition, the damage 
in the osseous part is not regenerated, but rather replaced by fibrous scar tissue (Bobic 
1999). Aseptic osteonecrosis, as in the case of osteochondritis dissecans, represents 
a special type of osteo-chondral defects. In this case, necrosis develops via a reduced 
blood supply in the area of insufficiently nourished subchondral bone, which eventually 
loosens together with its attached cartilage and turns into a painful flake in the joint 
space (Mubarak und Carroll 1981). 
 
Figure 2: Principally there are two types of cartilage 
damage: 1. Only the cartilage itself is damaged or 2. The 
subchondral bone is injured as well. In the second case, 
MSCs immigrate into the defect area and form 
fibrocartilaginous tissue (Khan et al. 2008). 
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2.5 Cartilage degeneration 
Age-adapted, physiological adjustments of cartilage metabolism may lead to cartilage 
degeneration with structural, morphologic, and functional changes. Therefore, the 
senior population carries an increased risk of suffering from degenerative processes. 
However, secondary cartilage damage can also appear in young patients, e.g. after 
infections, improper treatment of biomechanical deviations or impingement of the joint 
(Bedi et al. 2013). 
The end stage of all physiological and pathological cartilage erosion is osteoarthritis 
(OA)(Hayes et al. 2001, Tuan et al. 2013) with cartilage loss, a dysfunctional range of 
motion (ROM), and pain upon initiation of movements (Kleemann et al. 2005). OA is 
one of the most common joint diseases. As a result of previous cartilage damage, 
chondrocytes change their metabolism, which further contributes to the degeneration 
(Hart et al. 1999). This results in a reduced thickness of the cartilage. The collagen 
fibers network cannot withstand large strains any longer and proteoglycans are lost 
from the matrix. As a result, the pressure loading capacity of the cartilage is impaired, 
the tissue is progressively damaged and microcracks evolve. In the long run, a 
complete loss of the cartilage leads to pathological changes of the subchondral bone 
such as sclerosis, osteophyte formation, and subchondral cysts (Kleemann et al. 
2005). 
2.6 Treatment strategies 
Endoprosthetic total knee or hip arthroplasty is the treatment of choice for OA. 
However, the implantation of an endoprostheses should be delayed as long as 
possible, since they have a limited standing time and may thus eventually need to be 
revised (Goldring und Goldring 2007). 
Therefore, early-stage damage of the cartilage has to be treated with care and 
anticipation. Several established cell-based (e.g. (M)ACT, OAT), cell-free (e.g. bio-
engineered scaffolds, cell-free OCT from commercial banks) and stem cell-directed 
(micro-abrasion, Pridie-drilling) procedures compete for the best clinical outcome 
(Behery et al. 2014). 
2.6.1 Debridement and Lavage 
As this cleaning and rinsing technique of the joint only abates the pain and does not 
repair or regenerate damaged articular cartilage, it has only palliative character 
(Martinek et al. 2003). Using the mostly arthroscopic joint lavage, digestive, oxidative 
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enzymes derived from chondro-necrosis are removed. Debridement includes the 
removal of loose joint bodies and the smoothening of the cartilage surface, also called 
arthro-cleaning (Schinhan et al. 2012). 
2.6.2 Cartilage abrasion 
During the arthroscopic examination of a joint, it is a very common strategy to remove 
worn out layers of the cartilage and “refresh” the surface. This technique is very simple 
and fast, however it often does not yield a sufficient long-term outcome (Goymann 
1999). 
2.6.3 Microfracturing 
The concept behind this technique (sometimes referred to as Pridie-Drilling) is to 
enable mesenchymal stem cells to migrate into the damaged cartilage, to differentiate 
in this location, and to build new cartilaginous tissue. This technique has to be used 
with caution, as the replacing tissue often does not exactly match the properties and 
structure of the original cartilage, but rather represents fibrocartilaginous scar tissue 
(Oussedik et al. 2015). Considering the presence of progenitor cells in the superficial 
layer of the cartilage and their theoretical potential to form hyaline cartilage like 
structures, the contribution of this technique to an improved cartilage regeneration has 
also been questioned (Mesallati et al. 2015). 
2.6.4 Osteochondral autologous transplant (OAT) 
An osteochondral autologous graft of the size of the defect is harvested from a region 
of the joint that is less exposed to mechanical strains than the site of the original defect. 
Then the graft is inserted into the defect by the press-fit technique. One advantage of 
this method is a very good healing rate at the site of insertion. However, damage is 
intentionally caused in another joint area and the respective tidemarks of graft and 
defect are not always perfectly aligned (Lynch et al. 2015). 
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Figure 3: This scheme demonstrates the procedure of an OAT: First, an appropriate graft is harvested from a 
peripheral zone of the joint and then implanted at the site of the defect after preparing the recipient site in order to 
match the height of the graft (Fiedler 2014). 
2.6.5 (Matrix-associated) autologous chondrocyte transplantation (M) ACT 
In a first intervention, cartilage is arthroscopically harvested from the joint in an area 
less exposed to mechanical strain. Chondrocytes are then enzymatically liberated from 
the extracellular matrix and cultured for a period of 4 weeks. After this time, replicated 
chondrocytes are implanted into the site of damage. This is either done by placing tibial 
periosteum above the cartilage defect and fixing it with fibrin and injecting the 
chondrocytes into the resulting chamber or, alternatively, by seeding the cells onto a 
scaffold (matrix), which is subsequently inserted into the defect. This technique has 
demonstrated very good clinical results in several studies (Gillogly und Wheeler 2015, 
Gobbi et al. 2015), especially when treating defects with a diameter larger than 4 cm². 
Besides the size of the defect area, the location of the defect is a determining factor 
for the outcome of this technique. When repairing defects on the tibia, the patella or on 
multiple sites of the knee joint, clinical outcomes are not as good as for defects on the 
femur. Another pitfall of this cost-intensive procedure is that it requires two 
interventions (Dewan et al. 2014). 
Due to the immuno-evasive properties of cartilage, it is a tissue that may be suitable to 
a) be banked (in analogy to bone tissue) and b) to be transplanted as a xenograft in 
one-step operations. This would tremendously contribute to the practicability of this 
technique. 
2.6.6 Tissue-engineered scaffolds 
Hyaline cartilage is a bradytrophic tissue and endogenous regeneration of large 
defects normally results in fibrocartilaginous tissue formation (Triche und Mandelbaum 
2013). This is aggravated by the fact that cartilage damage is very common and 
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regularly leads to the development of OA (Demoor et al. 2014). As a consequence, 
current research focuses on the improvement of established treatment strategies and 
the development of new treatment approaches in tissue engineering (Mollon et al. 
2013, Tuan et al. 2013). Tissue-engineered scaffolds are designed to imitate the 
structure of the cartilage in order to support chondrocyte migration into the tissue and 
the formation of high-quality hyaline cartilage. There is some evidence for good clinical 
outcomes when using such scaffolds, which stimulates further extensive research in 
this field (Lim et al. 2014). 
The advantages of the cell-free approaches are rapid commercial availability, 
convenience in handling and a one-time operation procedure. In addition, there is no 
need for autologous donor sites or tissue donors.  
One type of such cell-free constructs is a three-layer, stratified scaffold (MaioRegen®, 
Finceramica) (Fig. 4) (Berruto et al. 2014). Each layer is characterized by a defined 
proportion between hydroxyapatite (HA) and de-antigenated equine collagen 1, thus 
imitating either subchondral bone, tidemark or cartilage surrounding the recipient site 
(Kon et al. 2010). 
 
Figure 4: The three layers of the MaioRegen® scaffold and their composition are shown at a macroscopic and a 
molecular level (Kon et al. 2010). 
The cartilaginous layer, consisting of Type I collagen (100 %), has a smooth surface 
to guarantee low friction during joint movement. The intermediate layer (tide mark-like) 
consists of a combination of Type I collagen (60 %) and HA (40 %), whereas the lower 
layer consists of a mineralized blend of Type I collagen (30 %) and HA (70 %) 
reproducing the sub-chondral bone layer. Each layer is separately synthesized by a 
standardized process starting from an atelocollagen (a non-immunogenic collagen, 
isolated from equine tendon) aqueous solution (1% w/w) in acetic acid. The upper, 
non-mineralized chondral layer only consists of type I collagen (Opocrin S.p.A., 
Modena, Italy), the intermediate and the lower layers are obtained by nucleating bone-
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like, nanostructured, non-stoichiometric HA into self-assembling collagen fibers, similar 
to the process during biological neo-ossification. The final construct is obtained by 
physically combining the layers on top of a Mylar sheet under freeze-drying and 
gamma-sterilization at 25 kGy (Kon et al. 2009).  
There are currently no data describing the specific behavior of this product in a detailed 
experimental in vitro model, but several studies have used this product either in 
experimental in vivo studies or in the clinical setting (Delcogliano et al. 2014, Filardo et 
al. 2013, Kon et al. 2010). The failure of the top layer of this product to fully reproduce 
the principal anatomical features of hyaline cartilage tissue is a known bio-technical 
limitation (Brix et al. 2016).   
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3 OBJECTIVES OF THE STUDY 
The objectives of this study were to analyze the behavior of the osteochondral implant 
system MaioRegen® for the first time in an in vitro model and use the results as a basis 
for future preclinical and clinical studies assessing its suitability for the therapy of 
osteochondral defects (Berruto et al. 2014). 
 
The following working hypotheses were tested: 
1. The experimental in vitro model is suitable for multimodal and high-throughput pre-
testing of implants intended for the clinical regeneration of osteochondral defects 
2. The OAT group is a suitable and representative control group by mimicking the 
clinically established treatment concept of osteochondral autologous transplantation 
3. MaioRegen® supports the regeneration of the osteochondral defect (incl. cell 
migration and tissue formation) in the in vitro model by its three-layered 
physicochemical and molecular structure     
4. The combination of histology, RT-PCR, biochemistry, and biomechanical testing is 
sufficient to address the behavior of the ‘host’ osteochondral cylinder and the implant, 
as well as potential reciprocal cross-talk. 
 
For this purpose, a novel osteochondral implant model was developed based on 
osteochondral cylinders resected from bovine femoral condyles using standardized 
punches. The cylinders were then filled with either the OAT implant or the MaioRegen® 
scaffold and cultured for periods of up to 10 weeks. 
After 0, 4, 8 and 10 weeks, samples were subjected to (immuno-) histological 
examinations (HE, Safranin-O; aggrecan staining) and biomechanical testing. In 
addition, they were analyzed at a transcriptional (gene expression of collagen 1, 
collagen 2, aggrecan, and COMP) and protein level (DAB- test for tissue proteoglycan 
analysis; ELISA for collagen 1, collagen 2, and aggrecan in supernatants; Fig. 5). 
The major advantages of the novel model are: a) it mimicks the in situ interactions of 
the recipient site and osteochondral implants; b) it allows to separately investigate each 
tissue component of the recipient cylinder and the implant; c) it permits to explore local 
cross-talk between the corresponding tissue type of recipient cylinder and implant. 
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Figure 5: Principal workflow for the preparation, cultivation and analysis of the in-vitro model for the investigation 
of either MaioRegen® scaffolds or OAT cylinders. I= osteochondral cylinder, II= autologous osteochondral 
implant/ transplant (OAT), III= MaioRegen® scaffold 
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4 MATERIALS AND METHODS 
4.1 Materials 
4.1.1 Chemicals, solutions, and cell culture medium 
Name Company 
Acetone Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Agarose-Gel  Invitrogen™, Carlsbad,CA,  USA 
Aquatex™ Merck KGaA, Darmstadt, Germany 
β – Mercaptoethanol  Sigma-Aldrich™, St. Louis, MO, USA 
Basic solution Heraeus Kulzer GmbH, Hanau, Germany, Technovit 9100® 
Chondroitinase ABC from Proteus Sigma-Aldrich™, St. Louis, MO, USA 
Dako Proteinase K Dako™-Agilent technologies, Hamburg, Germany 
3,3’ Diaminobenzidine tablets Sigma-Aldrich™, St. Louis, MO, USA 
1,9- Dimethyl-Methylene Blue zinc chloride double 
salt 
Sigma-Aldrich™, St. Louis, MO, USA 
Dimethybenzol Carl Roth GmbH + Co. KG, Karlsruhe, Xylene- Isomere 
Cell-Culture Medium solution 
gibco® by life technologies™, Darmstadt, Germany, DMEM/F-
12 (1:1) (1X) + GlutaMAX™ -I 
EDTA dinatriumsalz dihydrat Carl Roth GmbH + Co. KG, Karlsruhe 
Eosin Hollborn & Söhne GmbH & Co. KG, Leipzig, Germany 
Ethanol > 99.5% Carl Roth GmbH + Co. KG, Karlsruhe 
Fast Red TR/ Naphtol AS-MX Sigma-Aldrich™, St. Louis, MO, USA 
FBS- Fetal Bovine Serum Lonza™, Basel, Switzerland, FBS- BioWhittaker® 
Gentamicin  gibco® by life technologies™, Darmstadt, Germany 
Glycine Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Goat serum Dako™-Agilent technologies, Hamburg, Germany 
Guanidium chloride Merck KGaA, Darmstadt, Germany 
Guanidinium-thiocyanate Life technologies™, Carlsbad,CA,  USA, TRIzol® 
Hardener One  Heraeus Kulzer GmbH, Hanau, Germany, Technovit 9100® 
Hardener Two  Heraeus Kulzer GmbH, Hanau, Germany, Technovit 9100® 
Hematoxyline  Hollborn & Söhne GmbH & Co. KG, Leipzig, Germany 
Hydrochloric acid  Carl Roth GmbH + Co. KG, Karlsruhe, Germany, fuming 37 % 
iQ™ SYBR® Green Supermix Bio Rad Laboratories, Inc., Hercules, CA, USA 
Isotype Antibody  Sigma-Aldrich™, St. Louis, MO, USA, (goat anti mouse IgG) 
Isotype Antibody Dako™-Agilent technologies, Hamburg, Germany, (rabbit IgG) 
Insulin, Transferrin, Selen (ITS) Lonza™, Basel, Switzerland, FBS- BioWhittaker® 
K-Mount powder/ solution Not applicable 
Light green-solution Hollborn & Söhne GmbH & Co. KG, Leipzig, Germany 
Osteodec Labolan®, Navarra, Spain 
PMMA-powder Heraeus Kulzer GmbH, Hanau, Germany, Technovit 9100®  
Primary anti-aggrecan antibody  Sigma-Aldrich™, St. Louis, MO, USA, (rabbit anti Aggrecan) 
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Primary anti-collagen 1 antibody  Sigma-Aldrich™, St. Louis, MO, USA, (rabbit anti Collagen I) 
Primary anti-collagen 2 antibody  
Acris Antibodies, Inc., San Diego, CA, USA, (BP8008 α type II 
Collagen) 
Proteinase K - concentrate Dako™- Agilent technologies, Hamburg, Germany 
Regulator  Heraeus Kulzer GmbH, Hanau, Germany, Technovit 9100® 
Cell buffer Qiagen™, Venlo, Netherlands, RLT-Buffer 
RNA extraction kit Qiagen™, Venlo, Netherlands, RNeasy® Mini Kit 
Phenol/Chloroform 
Carl Roth GmbH + Co. KG, Karlsruhe, Germany, Roti®-
Phenol/Chloroform 
Safranin- O solution Hollborn & Söhne GmbH & Co. KG, Leipzig, Germany 
Secondary antibody Aggrecan  
Dako™-Agilent technologies, Hamburg, Germany, (goat anti 
rabbit) 
Secondary antibody Collagen I /II  
Dako™-Agilent technologies, Hamburg, Germany, (goat anti 
rabbit) 
Sodium chloride Merck KGaA, Darmstadt, Germany 
RNA amplification kit 
Invitrogen™, Carlsbad,CA,  USA, SuperScript® RNA 
Amplification Kit 
Trisaminomethane hydrochloride Sigma-Aldrich™, St. Louis, MO, USA, TRIS-buffer 
Hydrogen Peroxide Sigma-Aldrich™, St. Louis, MO, USA, H2O2, 3% 
Table I: Chemicals, solutions and cell culture medium 
4.1.2 Instruments 
Name Company/ Product Other specifications 
Microscope with camera 
Carl Zeiss AG, Oberkochen, Germany, 
AxioCam HRc 
 
Microscope 
Carl Zeiss AG, Oberkochen, Germany, 
Axiophot Microscope 
 
Centrifuge  
Eppendorf AG, Hamburg, Germany, 
Centrifuge 5415 D 
 
Centrifuge 
Eppendorf AG, Hamburg, Germany, 
Centrifuge 5810 R 
 
Desiccator 
ThermoScientific®, Waltham, MA, USA, 
Nalgene™ Classic Desiccator 
 
Digital Slide Scanner 
Hamamatsu®, NanoZoomer-XR Digital 
slide scanner C12000, , Japan 
 
Freezer Cryo Freezer (-80°C) set at -80°C 
Microplate reader 
BMG Labtech GmbH, Ortenberg, 
Germany, FLUOStar Optima 
 
Freezer  Cryo Freezer (-20°C) Set at -20°C 
Incubator 
Heraeus, Kleinostheim, Germany, Hera 
cell®_1 - incubator 
Temp.:36.5°C,  
5.0% CO2 
Incubator 
Memmert, Schwabach, Germany, CO2 
incubator INCOmed 
 
Magnetic stirrer 
Heidolph Instruments GmbH & Co.KG, 
Schwabach, Germany, MR3001 
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Microtome 
Microm, Walldorf, Germany, HM 355- 
Micromtome 
 
Cell culture bench Clean Air™, Sanford, Maine, USA  
Cycler 
Bio Rad Laboratories, Inc., Hercules, 
CA, USA, Mastercycler iCycleriQ® 
 
Pipette 
Brand GmbH & Co. KG, Wertheim, 
Germany, Accu-jet 
 
Multi-channel pipettes Eppendorf AG, Hamburg, Germany 
Variable Volumes: 1-10 
µl, 100-1000 µl  
Microdismembrator  Braun, Melsungen, Germany  
pH Meter 
Mettler- Toledo, Columbus, Switzerland, 
pH Meter MP 220 
 
Refrigerator  Siemens AG, Düsseldorf, Germany set at 7°C 
Sterile set of instruments 
(scalpel, forceps) 
Schubert & Weiss GmbH, Munich, 
Germany 
 
Single channel pipettes Eppendorf AG, Hamburg, Germany 
Variable Volumes: 2-20 
μl, 10-100 μl, 20-200 μl, 
100-1000 μl  
Spectrophotometer  
Peqlab, Biotechnologie GmbH, 
Erlangen, Germany, Spectrophotometer 
Nano Drop® ND- 1000 
 
Thermomixer  
Eppendorf AG, Hamburg, Germany, 
Thermomixer (comfort) 
1.5 ml and 2.0 ml 
Shaker 
Scientific Industries Inc., New York, 
USA, Vortex Genie 2 
120 V, 60 Hz 
Scale 
Sartorius, Göttingen, Germany, Weight 
scale BP 211 D 
 
Universal testing machine Fa. Zwick, Ulm, Germany, Zwicki 1120  
Table II: Instruments 
4.1.3 Consumables 
Name Company/Product 
ELISA Detection Kit Blue Gene,  
Bone Graft Harvester  Arthrex™ Med. Inst. GmbH, Karlsfeld 
Bone Graft Harvester  Arthrex™ Med. Inst. GmbH, Karlsfeld 
Bovine knee joints  
Fleischerei Zitzmann, Erfurt, Germany AND 
Schlachthof Weibersheim 
Tubes BD Biosciences, Heidelberg, Germany, Falcon® tubes 
Scaffold Finceramica, Faenza, Italy, MaioRegen® 
Suspension-Culture-Plate Greiner bio-oneCELLSTAR® 
Parafilm “M” BEMIS 
Petri-dish BD Biosciences, Heidelberg, Germany, BD Falcon™ 
Pipette filtered tips Eppendorf AG, Hamburg, Germany, Filtertips 
Pipette tips 
Greiner Bio –One GmbH, Frickenhausen, Germany, Sterile tips 
CellStar™ 
Microscope slides Gerhard Menzel GmbH, Braunschweig     
ELISA Detection Kit Chondrex, Inc. Redmond, WA, USA    
Table III: Consumables 
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4.1.4 Software 
Name Company Version 
AxioVision 
Carl Zeiss Microscopy GmbH, 
Oberkochen, Germany 
4.8.3. SP1  
Excel® Microsoft Inc., Redmond, WA, USA Microsoft Office 2010 
iCycler iQ™ 
Bio Rad Laboratories, Inc., Hercules, 
CA, USA 
3.1 
MARS Data Analysis Software 
BMG Labtech GmbH, Ortenberg, 
Germany 
2.40 
NDP-Viewer Hamamatsu®, Japan 2.0 
Optima 
BMG Labtech GmbH, Ortenberg, 
Germany 
2.20R2 
SPSS SPSS, Chicago, USA Win Version 22.0 
Table IV: Software 
4.2 Methods 
4.2.1 Preparation of bovine osteochondral cylinders and cell culture 
Bovine knee joints (German Holstein Friesian Cattle) were obtained on the day of 
slaughter. Osteochondral cylinders were aseptically prepared by punching out a 
central cylinder with a diameter of 6 mm and a length of 10 ± 0.2 mm using a 6 mm 
Bone Graft Harvester – Recipient punch system (Arthrex™). 
Another osteochondral punch with a diameter of 10 mm and a length of 10 ± 0.2 mm 
was then centered on the initial 6 mm punch, assuring a circular wall width of 2 mm 
(Fig. 5). After lifting the osteochondral rings off the underlying bone, they were stored 
in freshly prepared cell culture medium (gibco® by life technologies™; for composition 
see below). 
The scaffolds (MaioRegen®, Finceramica™) were first moistened with cell culture 
medium, then cut to a diameter of 6 mm using the appropriate donor punch (Arthrex™) 
and finally press-fit inserted into the osteochondral rings. As a control group, the 
previously harvested central cylinders were reimplanted into the osteochondral rings 
of their origin in analogy to the procedure during osteochondral autologous 
transplantation  and subsequently cultured as the scaffold group.  
Seventeen wells of a 24-well plate were then evenly filled with a total of 9 ml of hot 2% 
agarose (Invitrogen™). Before complete hardening of the gel, central cavities with a 
diameter of 10 mm were generated in the gel with a manufactured stamp (Fig. 6). The 
osteochondral rings were then embedded into the agarose cavities in an upright 
fashion, with the cartilage facing the top. This guaranteed a sufficient nutrition via 
diffusion and a stable footing against the shear forces during medium exchange. 
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Figure 6:  Cavities with a diameter of 10 mm were generated in the hot liquid agarose gel using this stamp. 
For each time point (4, 8 and 10 weeks) and each group (scaffold and OAT), an extra 
plate was prepared. The well plates were then covered and stored in an incubator 
(Heraeus®) at 37.5°C, 5% CO2 for 48 h with a cell culture medium exchange every 
second day. The supernatant of the wells was collected every other day, frozen and 
eventually used for analysis. 
Cell culture medium (500 ml Cell-Culture Medium DMEM/F-12(1:1) + GlutaMAX™ 
(gibco® by life technologies™), 25 ml FBS Bio- Whittaker® (Lonza™), 5 ml Gentamicin 
(gibco® by life technologies™) and 500 µl ITS (Lonza™)) was freshly prepared before 
initiating a new test series and before each medium exchange.  
4.2.2 Histology and immunohistochemistry 
Fresh, non-cultured (0 weeks), and cultured (4, 8, 10 weeks) implant-containing 
osteochondral rings were harvested and stored in 100 % acetone at -7°C for a period 
of at least 72 h. 
For further preparation, samples were transferred to fresh acetone (Carl Roth GmbH 
+ Co. KG) for one hour, before washing them twice in Xylene (Carl Roth GmbH + Co. 
KG) for an hour each. They were then incubated in a 1:1 acetone and basic solution 
(Heraeus Kulzer GmbH) mixture for 20 min.  
Samples were then immersed in basic solution and Hardener One (Heraeus Kulzer 
GmbH, concentration of 0.01 g/ml) for one hour before being rinsed with infiltration 
solution (Heraeus Kulzer GmbH, 25 ml Basic solution destabilized with Aluminum 
Oxide, 2 g PMMA powder (Heraeus Kulzer GmbH) and 0.1 g Hardener One). 
Thereafter, the samples were stored in a desiccator for 7 days.  
For embedding of the samples, two solutions A and B were prepared. Solution A was 
composed of 25 ml Basic solution, 4 g PMMA powder and 0.15 g Hardener One; 
solution B contained only 2.2 ml Basic solution, 0.2 ml Hardener Two and 0.1 ml of 
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Regulator solution.  Solutions A and B were mixed in a 9:1 ratio and used to fix the 
osteochondral cylinders. After 48 h of hermetically sealed storage at -7°C, the blocks 
were fixed in a mounting ring using K-Mount powder and solution.   
Blocks were then sectioned on a microtome and subsequently either fixed on Polysine 
or on Superfrost slides (Gerhard Menzel GmbH). 
Before staining, the histological sections were de-plastinated by incubating the 
sections at 37°C for 30 min and washing in Xylene for 2 x 20 min and M- acetate for 
20 min (Carl Roth GmbH + Co. KG). Sections were then washed with 96% alcohol for 
2 x 2 min (Carl Roth GmbH + Co. KG) and with 70% alcohol for 2 x 2 min. The samples 
were then rinsed with distillated water.  
Finally, the stained histological sections were evaluated using semi-quantitative 
scores. The cartilaginous parts were rated according to a modified O’Driscoll score.  
For the other parts, this scoring system was adapted in a reasonable manner. Due to 
the use of a score (that was actually designed to evaluate cartilage) in bone tissue, an 
increase in the score may implicate a differentiation in cartilage but a de-differentiation 
in bone (O'Driscoll et al. 1986).  In addition, other features such as the lateral bonding 
and cell migration were analyzed. For a better comprehension, scores for structural 
and regenerative features were summarized separately (Table 1 and 2). 
Tissue HE Safranin-O Aggrecan 
Cartilage Ring 
0 = intact lamina splendens  
1= loss of lamina splendens 
2= moderate cartilage erosion  
3= massive loss and destruction of 
cartilage. 
0= intact proteoglycan (PG) 
     structure   
1= slight PG loss 
2= moderate PG loss  
3= massive PG loss 
0= large aggrecan 
depositions 
1= slight aggrecan loss 
2= moderate aggrecan loss 
3= massive  
Bone Ring 
0= intact lamellar bone  
1= slightly decreased bone density (single 
foci)  
2= decreased bone density (several foci)  
3 =  osteoporotic, (necrotic) bone tissue 
not applicable not applicable 
Implant 
cartilaginous part 
0= intact implant 
1= slightly dissolving implant/tissue 
2= massive dissolution of implant  
3= complete loss of implant 
0= intact proteoglycan (PG) 
      structure   
1= slight PG loss 
2= moderate PG loss  
3= massive PG loss  
ONLY FOR OAT GROUP 
0= large aggrecan 
depositions 
1= slight aggrecan loss 
2= moderate aggrecan loss 
3= massive 
ONLY FOR OAT GROUP 
Implant osseous 
part 
0= intact implant 
1= slightly dissolving implant/tissue 
2= massive dissolution of implant  
3= complete loss of implant 
not applicable not applicable 
Table 1: Scoring system for the structural/ histological evaluation of the histological sections.  
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Tissue HE Safranin-O Aggrecan 
Cartilage Ring 
0= no lateral bonding 
1= partial bonding 
2= strong bonding 
3= complete tissue integration 
not applicable not applicable 
Bone Ring 
0= no lateral bonding 
1= partial bonding 
2= strong bonding 
3= complete tissue integration 
0= no PG  
1= single PG structures  
2= connected PG structures  
3= large, dominating PG structures 
0 = no signal 
1= insular foci  
2= numerous foci  
3= large deposits 
Implant 
cartilaginous part 
0= no cells migrated  
1= single cells migrated  
2= numerous cells migrated 
3= complete layer/ organized 
     network of migrated cells.  
0= no PG  
1= single PG structures  
2= connected PG structures  
3= large, dominating PG structures 
ONLY FOR MAIOREGEN  
0 = no signal 
1= insular foci  
2= numerous foci  
3= large deposits 
ONLY FOR MAIOREGEN 
Implant osseous 
part 
0= no cells migrated  
1= single cells migrated  
2= numerous cells migrated 
3= complete layer/ organized 
     network of migrated cells.  
0= no PG  
1= single PG structures  
2= greater, connected PG structures  
3= large, dominating PG structures 
0 = no signal 
1= insular foci  
2= numerous foci  
3= large deposits 
Table 2: Scoring system for the histological evaluation with focus on regenerative features.  
4.2.2.1. Hematoxyline Eosin (HE) - Staining 
De-plastinated sections were washed in distillated water for 30 min and then dipped 
into Hematoxylin (Hollborn & Söhne GmbH & Co. KG) for 20 s before washing them in 
water (aqua nondest) for 10 min. After this step, the sections were incubated in Eosin 
(Hollborn & Söhne GmbH & Co. KG) for 10 s and rinsed again with water. Thereafter, 
sections were passed through ascending concentrations of alcohol ending in xylene 
(starting with Isopropanol (2-propanol) twice for 2 minutes, followed by 96% ethanol 
for 2 minutes and xylene twice for 5 min. Finally, the stained sections were covered or 
embedded with mounting media (Aquatex®, Merck AG). 
4.2.2.2. Safranin-O Staining 
De-plastinated sections were stained in Safranin- O solution (Hollborn & Söhne GmbH 
& Co. KG) for 4 min, washed in distilled water and then incubated in Light-Green 
(Hollborn & Söhne GmbH & Co. KG) for another 4 min before passing them through 
the same ascending alcohol concentrations as above. 
4.2.2.3. Immunohistological staining  
For aggrecan staining, histological sections were enzymatically digested by 
Chondroitinase ABC (Sigma- Aldrich™) 1:40 in 0.1 M Tris-HCl for 90 min at 37°C 
before decalcifying them in Osteodec (Labolan®) at 37°C for 1 h. After this and all 
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following steps, sections were washed in TBS buffer solution (pH =7.4).  Thereafter, 
the endogenous peroxidase was blocked with 3% H2O2 (Sigma- Aldrich™) and 
nonspecific binding sites were blocked by 10% goat serum (Sigma- Aldrich™). 
Aggrecan was detected by Aggrecan Primary Antibodies 1:50 in TBS (Sigma- 
Aldrich™). Subsequently the sections were incubated over night at 4°C with Iso-goat-
anti-mouse IgGs 1:1000 in TBS (Dako™- Agilent technologies).  
The following day, the sections were incubated with amplifying, secondary antibodies 
of the aggrecan system (Dako™- Agilent technologies; dilution 1:30 in TBS) and then 
stained with Fast Red for aggrecan (Sigma- Aldrich™). The sections were then 
counterstained with hematoxylin, washed in tap water, and covered with Aquatex 
(Merck KG). 
4.2.3 RNA isolation 
Osteochondral samples containing implants were dissected into cartilage ring, implant 
top (either the upper, collagen-enriched layer of the MaioRegen scaffold implant or the 
cartilaginous part of the OAT implant), bone ring and implant bottom (either the lower, 
hydroxylapatite-containing layers of the scaffold or the osseous part of the OAT 
implant) as shown in Fig. 4 and 5. The samples were then separately vortexed for one 
minute in lysis- buffer consisting of 4950 µl RLT- buffer (Qiagen™) and 50 µl β– 
Mercaptoethanol (Sigma- Aldrich™). Implant top and bottom were then shock frozen 
in liquid nitrogen, whereas cartilage rings and bone rings were separated from the lysis-
buffer first before shock freezing each, tissue and buffer. 
Cartilage rings, bone rings, implant top and bottom were transferred into Trizol® (Life 
technologies™), mechanically broken up using scissors or a microdismembrator 
(Braun®). There bone tissue was milled for 1 min with an agitated grinding ball in a 
nitrogen-cooled, stainless steel container at a frequency of 33 Hz and an amplitude of 
18 mm. Thereafter, the samples were centrifuged at 12 x 10³ rpm for 3 min before 
transferring the supernatants into 180 µl of phenol chloroform (Carl Roth GmbH + Co. 
KG). There probes were then incubated for another 3 min before centrifuging at 12 x 
10³ rpm with a Centrifuge 5415 D (Eppendorf AG ) for 10 min. The upper layer of the 
resulting tri-layered solution was then transferred to 300 µl of 80% ethanol. The RNA 
isolated from the lysis-buffer-solutions of the cartilage and bone rings were directly 
used for subsequent RNA isolation. 
The following procedure of RNA isolation was performed using an RNA extraction kit 
in accordance with the instructions of the supplier (Qiagen™). In detail, the RNA 
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containing ethanol solution was transferred onto an RNeasy column® and 
subsequently centrifuged at 1 x 104 G for 1 min. The throughput was discarded and 
the column rinsed with 500 µl of RW1® buffer solution. The columns were then again 
centrifuged at 1 x 104 G for 1 min. A total of 70 µl of RDD buffer® and 10µl of DNase 
1® were added to the column, which was then incubated for 15 min. The column was 
then washed with 500 µl of RW1 buffer® and centrifuged 1 x 104 G for 30 s. This step 
was repeated three times. Then the column was centrifuged at 1.2 x 104 G for 2 min, 
transferred into a new Eppendorf® tube, and rinsed with 15 µl RNase-free water. RNA 
was eluted by centrifugation at 1 x104 G for 1 min. 
Finally, the concentration of the purified RNA was measured using the NanoDrop ND- 
1000 (Peqlab, Biotechnologie GmbH). 
4.2.4 Reverse transcription and quantitative PCR 
Total RNA eluate (15 μl) was primed with oligo(d)T (Invitrogen™) and reverse-
transcribed for one hour at 42°C using SuperScript-II reverse transcriptase 
(Invitrogen™). 
qPCR reactions were carried out as previously described with cloned standards for the 
quantitation of bovine collagen 1, collagen 2, aggrecan, COMP and the housekeeping 
gene bovine Aldolase.  qPCR was then performed on a Mastercycler iCycleriQ® (Bio 
Rad Laboratories, Inc.) with the primer pairs and PCR conditions presented in Table 
3.  
For the evaluation collagen 2/1 and aggrecan/collagen 1 ratios were calculated. In 
cartilaginous tissues, scores larger than 1 indicate differentiating processes; in 
osseous tissues, however, scores smaller than 1 indicate differentiating processes.  
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Table 3: General amplification protocol (45 cycles): initial denaturation for 2 min at 96°C, specific primer 
annealing temperature as stated above for 20 s, amplification at 68°C for 15 s, additional heating to 5°C below the 
melting temperature of the PCR product as above. General melting curve protocol (one cycle): denaturation for 1 
s at 95°C; cooling to 5 °C above the primer annealing temperature (holding temperature for 10 s); heating to 95°C 
(0.1°C/s); final cooling over 8 min to 40°C. 
The relative concentrations of cDNA present in the samples were calculated using the 
standard curves. For the normalization of the cDNA concentration in each sample and 
the comparability of the calculated mRNA expression in the analyzed samples, the 
housekeeping gene aldolase was also amplified.  Product specificity was confirmed by 
melting curve analysis and initial cycle sequencing of the PCR products. 
4.2.5 Enzyme-linked immunosorbent assay (ELISA) 
The medium supernatants of the culture medium exchange of weeks 0, 4, 8 and 10 
were analyzed by pooling supernatants of the same week and group. 
Collagen 1, collagen 2 and aggrecan concentrations in the supernatants of the culture 
medium were measured according to the protocols of commercially available ELISA-
Kits (Chondrex™, BlueGene).  
Absorption was measured using a Fluostar Optima™ Reader (BMG Labtech GmbH) 
at 490 nm. 
4.2.6 Quantification of glycosaminoglycans 
For the quantification of sulphated glycosaminoglycans, the dimethylene blue binding 
assay (DMB) was used (Chandrasekhar et al. 1987). Samples were mechanically 
broken up into their subparts (cartilage ring, implant top, bone ring and implant bottom), 
incubated in 1 ml guanidium hydrochloride (Merck KGaA) at 4 °C for 48 h, centrifuged 
at 12 x 10³ rpm for 1 h (centrifuge 5810 R, Eppendorf AG), and finally eluted in 700 µl 
H2O each.  
Gene Primer 5’ -> 3’ Primer 3’ -> 5’ Product length 
in bp 
T annealing in 
°C 
Melting T 
product in °C 
Aldolase CGC CCC CGA TGC AGG 
GAT TC 
CAC CGG ATT GTG GCT CCG 
GG 
314 58 88 
COMP ATG CGG ACA AGG TGG 
TAG AC 
TCT CCA TAC CCT GGT TGA 
GC 
498 58 94 
Aggrecan CAG AGT TCA GTG GGA 
CAG CA 
AGA CACA CCA GCT CTC 
CTG AA 
189 60 84 
Collagen I ACA CAG GTC TCA CCG 
GTT TC 
AGC CAG CAG ATC GAG AAC 
AT 
185 60 86 
Collagen II CAT CTG GTT TGG AGA 
AAc CAT C 
GCC CAG TTC AGG TCT CTT 
AG 
600 61 83 
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For the supernatants of the cartilage and bone lysis-buffer the quadruplicated volume 
of Acetone (Carl Roth GmbH + Co. KG) was added and incubated for 30 min at -20 °C 
before centrifugation at 12 x 10³ rpm for 10 min (Centrifuge 5810 R Eppendorf AG). 
The remaining pellet was then washed in 500 µl Ethanol (70%) and again centrifuged 
for 5 min at 12 x 10³ rpm. Supernatants were discarded and the pellet resuspended in 
100 µl distilled H2O. 
For the DMB assay, 16 mg 1,9 Dimethylene Blue (Sigma- Aldrich™) were dissolved in 
5 ml Ethanol (100%) and 2.37 g NaCl (Merck KG) and 3.04 g Glycine were added (Carl 
Roth GmbH + Co. KG). The resulting solution was diluted in distilled H2O to a total 
volume of 1 l (pH 3). 
Absorption was measured using a Fluostar Optima™ Reader (BMG Labtech GmbH) 
at 525 nm, taking a descending dilution series of bovine nasal septum as a standard. 
4.2.7 Biomechanical analysis 
Biomechanical testing of samples from the different time points and test series (10 
samples each) was performed using a static universal testing machine Zwicki 1120® 
at the Department of Biomechanics, Technische Universität München. The 
osteochondral cylinder was fixed and the force necessary to push out the implant from 
the osseous side with a stamp (5 mm diameter) was measured. Thereafter, the stamp 
was passed through the empty cylinder without an implant. This value (Fmax(empty)) was 
subtracted from the value of the ring still containing an implant (Fmax(insert)). Therefore, 
the adjusted value for the biomechanical load bearing capacity of the implant was ΔF 
= Fmax(insert) - Fmax(empty). 
4.2.8 Statistics 
All the data were entered into an Excel database (MS Office Excel 2007, Microsoft, 
Redmond, Washington). Statistical analysis was performed using a nonparametric 
Friedman test to detect differences among multiple test groups and, subsequently, 
using a nonparametric Wilcoxon-Mann-Whitney test for the comparison of individual 
groups. P values ≤ 0.05 were considered statistically significant.  
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5 RESULTS 
5.1 Histology 
5.1.1 Overview of HE, Safranin-O and Aggrecan (immuno-)stainings 
t in weeks OAT MaioRegen 
0   
4  
 
8 
 
 
10 
 
 
Fig. 7: Overview of OAT and MaioRegen sections at 0, 4, 8, and 10 weeks (HE-staining; Magnification 9x). 
32  
 
t in weeks OAT MaioRegen 
0 
  
4 
 
 
8 
 
 
10 
 
 
 
Fig. 8: Overview of OAT and MaioRegen sections at 0, 4, 8, and 10 weeks (SO-staining; Magnification 9x). 
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Fig. 9: Overview of OAT and MaioRegen sections at 0, 4, 8, and 10 weeks (aggrecan immunostaining; 
Magnification 9x). 
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The data for the semiquantitative histological description are provided in Tables 4 and 
5 (see below) and are based on semiquantitative scores (see Methods; Tables 1 and 
2). 
Cartilage ring 
HE staining: In both the OAT and the MaioRegen group, the cartilage rings largely 
maintained their shape (Fig. 7). In addition, no signs of necrosis or tissue degeneration 
were observed, except for occasional empty chondrocyte lacunae. Those were found 
especially in the surface and transitional layer. This overall largely maintained tissue 
integrity was reflected by low tissue degradation scores between 0 and 0.3 in the OAT 
group and between 0 and 1.1 in the MaioRegen group (Table 4).  
In both the OAT and the MaioRegen group, the gap between the cartilage ring and the 
implants was maintained until 10 weeks of culture and did not show any signs of tissue 
formation and/or wound healing. Migration of cells onto the cartilage ring was observed 
in both groups (Abb. 7).  
This very limited degree of regeneration was reflected by a low and similar 
regeneration score for both OAT and MaioRegen (range 0 to 0.6; Table 5). 
Safranin-O staining: In the OAT and the MaioRegen group, there was a clear decrease 
of the staining intensity over time in the cartilage ring, which is indicative for a loss of 
proteoglycan (Fig. 8). Semiquantitative evaluation confirmed a slight to moderate and 
comparable loss of proteoglycans in both groups (0 to 1.4 for OAT; 0 to 0.8 for 
MaioRegen; Table 4). 
Aggrecan staining: In agreement with the results of the Safranin-O staining, the 
aggrecan staining in the OAT group was lost over time and initially large, cohesive 
aggrecan deposits seemed to be redistributed into smaller, multifocal insulae. At 8 
weeks, aggrecan staining was primarily observed in the immediate vicinity of the 
chondrocytes, possibly indicating active cellular aggrecan synthesis (Fig. 9).  
These changes resulted in a progressively increased score for the proteoglycan loss 
for the OAT group from 0 at 0 weeks to 2.0 at 8 weeks (Table 4). 
Similar, but quantitatively smaller changes were also observed in the MaioRegen 
group (Fig. 9). In contrast to the OAT group, however, intense aggrecan signals were 
found at the interface between the cartilage ring and the cartilaginous part of the 
MaioRegen scaffold throughout culture (Fig. 9). Also in the MaioRegen group, the 
score for the aggrecan loss increased from 0 at 0 weeks to 1.6 at 10 weeks (Table 4).
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Bone ring 
HE staining: In both the OAT and MaioRegen group, also the bone rings maintained 
their original structure without signs of necrosis or other bone-degrading processes 
(Fig. 7). This was reflected by low tissue degradation scores between 0 and 0.3 for the 
OAT group and 0 and 1.0 for the MaioRegen group (Table 4).  
In the OAT group, the gap between the bone ring and the implant was continuously 
closed within 8 weeks of culture. At this time point, the gap between the osseous parts 
of the implant model could hardly be recognized any more. In addition, cell migration 
into the neighboring subchondral regions was observed (Fig. 7). 
This almost complete closure of the gap was reflected by a very high lateral 
bonding/regeneration score (up to 2.6 of max. 3; Table 5). 
In the MaioRegen group, in contrast, the gap between bone ring and implant was even 
enlarged with time, at least partially caused by progressive dissolution of the 
MaioRegen implant. At the same time, the adjacent bone ring showed clear signs of 
bone formation, as indicated by a diminished size of the original defect and by a 
condensed edge region with newly formed bone trabeculae (Fig. 7). 
This active process resulted in a lack of lateral bonding to the bone ring (significantly 
lower than in the case of OAT), but a substantial immigration into the implant (see 
below; Table 5). 
Safranin-O staining:  
In contrast to the proteoglycan loss in the cartilage ring, both OAT and MaioRegen 
showed a transient, moderate increase of the proteoglycan-containing cartilage 
structures with a peak/plateau at 4 weeks, possibly reflecting an attempt to integrate 
the implant via enchondral ossification (Fig. 8). This resulted in a proteoglycan 
deposition score of max. 1.6 for OAT and 1.1 for MaioRegen (Table 5).  
Aggrecan staining: In both the OAT and the MaioRegen group, the bone ring showed 
aggrecan signals after 4, 8, and 10 weeks in the areas corresponding to the enhanced 
proteoglycan deposition detected by Safranin O staining (Fig. 9). However, this was 
more pronounced in the case of MaioRegen (max. 2.3 for MaioRegen versus max. 1.6 
for OAT; Table 5). 
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Implant cartilaginous part 
HE staining: In analogy to the cartilage ring of the neighboring osteochondral cylinder, 
the cartilaginous part of the OAT implant almost fully maintained its tissue integrity 
without any signs of necrosis or tissue degradation (Fig. 7), and thus showed very low 
tissue degradation scores (between 0 and 0.3; Table 4). 
In addition, moderate cell migration onto the surface of the OAT implant was observed, 
reflected in a score of max. 1.1 (Table 5). 
Due to its progressive dissolution over time, the ‘tissue’ integrity of the cartilaginous 
part of the MaioRegen group was partially or totally lost at 10 weeks (degeneration 
score of up to 1.4; Table 4). In parallel, there was hardly any cell migration onto this 
implant part (max. 0.1; Table 5). 
Safranin-O staining: As observed for the neighboring cartilage ring, the cartilaginous 
parts of the OAT implant showed a limited decrease of the staining intensity over time 
(Fig.  8; proteoglycan loss of max. 0.3 at 8 weeks; Table 4). Due to the complete 
absence of proteoglycan in the cartilaginous top of the MaioRegen group, hardly any 
positive Safranin-O staining was detected at any time point. 
Aggrecan staining: For both OAT and MaioRegen, the findings were largely 
comparable with those of the Safranin-O staining, with a slighty higher proteoglycan 
loss in the OAT group and a very restricted positive signal for aggrecan in the 
MaioRegen group (Fig. 9; Tables 4, 5). 
Implant osseous part 
HE staining: In the OAT group, the osseous part of the implant showed a stable 
structure without signs of necrosis or tissue degradation and thus a degeneration score 
of 0 (Fig. 7; Table 4).  
In contrast, the osseous part of the MaioRegen implant displayed slight dissolution 
(Fig. 7; max. score 0.6; Table 4), however less marked then for its cartilaginous 
counterpart (see Table 4). Cell migration onto both the OAT and MaioRegen implants 
was moderate and comparable (max. 1.5; Table 5). 
Safranin-O staining: The osseous part of both OAT and MaioRegen showed moderate 
to strong proteoglycan deposition with a peak or plateau at 4 weeks (Fig. 8; (Table 5). 
Aggrecan staining: In both the OAT and the MaioRegen group, there was a progressive 
appearance of positive aggrecan signals with a peak or plateau at 4 or 8 weeks, which 
37  
 
was reflected by progressively increasing scores over time  (from 0.3 to 2.1 for OAT 
and 0 to 2.0 for MaioRegen group; Table 5; Fig. 9).  
 
5.1.2 Results of semiquantitative evaluation 
After 0, 4, 8, and 10 weeks of cell culture, three investigators rated the histological 
sections according to scoring system presented in Tables 1 and 2 (see Methods).  
Tissue 
t in 
weeks 
HE Safranin-O Aggrecan 
OAT MaioRegen OAT MaioRegen OAT MaioRegen 
Cartilage rings 
0 
4 
8 
10 
0 
0.3 (± 0.5) 
0.2 (± 0.4) 
 
0 (± 0) 
1.1 (± 0.3) 
0.2 (± 0.4 ) 
0.6 (± 0.7) 
0 
0.4 (± 0.5) 
1.4 (± 0.5) 
 
0 
0.7 (±0.6) 
0.8 (± 0.3) 
0.7 (±0.4) 
2.4 (± 0.3) 
1.4 (± 0.5) 
2.0 (± 0) 
1.5 (± 0.5) 
1.4 (± 0.5) 
1.2 (± 0.4) 
1.6 (± 0.5) 
Bone rings 
0 
4 
8 
10 
0 
0.3 (± 0.5) 
0 
 
0 
0 
0 
1.0 (± 0.7) 
not applicable not applicable not applicable not applicable 
Implant 
cartilaginous 
part 
0 
4 
8 
10 
0 
0.4 (± 0.7) 
0 
0 
1.1 (± 0.8) 
1.4 (± 0.5)* 
1.4 (± 0.5) 
0 
0.2 (± 0.3) 
0.3 (± 0.4) 
not applicable 
2.0 (± 0.5) 
2.4 (± 0.5) 
1.0 (± 0) 
not applicable 
Implant 
osseous part 
0 
4 
8 
10 
0 
0 
0 
0 
0.6 (± 0.5) 
0.4 (± 0.5) 
0.5 (± 0.7) 
not applicable not applicable not applicable not applicable 
Table 4: Degradation of the involved tissue types and components, i.e., degeneration (HE), proteoglycan loss 
(Safranin-O staining), and aggrecan loss (Aggrecan staining). The respective scoring systems are shown in Table 
1 (see Methods). Generally, low values indicate an intact status. *p ≤ 0.05 versus OAT. 
Table 5: Regenerative properties of the involved tissue types and components, i.e., lateral bonding (cartilage/bone 
ring) and cell migration (implant; HE staining), as well as proteoglycan deposition (Safranin-O staining; Aggrecan 
staining). The respective scoring systems are shown in Table 2 (see Methods). Generally, high values indicate a 
higher degree of regeneration. *p ≤ 0.05 versus OAT.  
Tissue 
t in 
weeks 
HE Safranin-O Aggrecan 
OAT MaioRegen OAT MaioRegen OAT MaioRegen 
Cartilage ring 
0 
4 
8 
10 
0 
0.6 (± 0.4) 
0.3 (± 0.3) 
 
0 
0 
0 
0 
not applicable  not applicable not applicable  not applicable  
Bone ring 
0 
4 
8 
10 
0 
2.2 (± 0.3) 
2.6 (± 0.5) 
0 
0* 
0* 
0 
0.7 (±0.4) 
1.6 (± 0.5) 
1.6 (± 0.5) 
 
0.5 (± 0.5) 
0.8 (± 0.3) 
1.1 (± 0.3) 
1.1 (± 0.3) 
0.4 (± 0.5) 
1.6 (± 0.5) 
0.6 (±0.4) 
0.6 (± 0.5) 
2 (± 0.7) 
1.8 (± 0.6) 
2.3 (± 0.5) 
Implant 
cartilaginous 
part 
0 
4 
8 
10 
0 
0.7 (± 0.6) 
1.1 (± 0.9) 
 
0 
0 
0* 
0.1 (± 0.1) 
not applicable 
0 
0.1 (± 0.3) 
0 
0 
not applicable 
0 
0.3 (± 0.5) 
0.2 (± 0.4) 
0.1 (± 0.3) 
Implant 
osseous part 
0 
4 
8 
10 
0 
0.7 (± 0.4) 
1.5 (± 0.5) 
 
0 
1.4 (±0.5) 
1.4 (±0.5) 
1.5 (± 0.5) 
0.8 (± 0.3) 
2.6 (±0.5) 
2.7 (±0.4) 
 
0* 
2.4 (± 0.5) 
1.7 (± 0.4) 
1.4 (± 0.5) 
0.3 (± 0.5) 
2.1 (± 0.6) 
0.8 (± 0.4) 
0 
1.7 (± 0.4) 
2.0 (± 0) 
1.6 (± 0.5) 
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5.2 Quantitative RT-PCR 
In order to improve visualization and comprehension of the PCR data, small schemes 
of the respective parts of the osteochondral cylinder and the implants were inserted. 
 
Figure 10: Histological section and simplified scheme specifying the 6 diverse types of tissues/ implant material 
that were analyzed for gene expression of collagen 1, collagen 2, aggrecan, and COMP. 
5.2.1 Cartilage ring 
Collagen 1 
In the OAT group, collagen 1 mRNA was detected at 4 weeks only, 
while the MaioRegen group showed a consistently and significantly 
decreasing mRNA expression from 0 to 10 weeks (Fig. 11). 
Collagen 2 
Collagen 2 gene expression was approx. 100-fold increased over time in both groups, 
with a peak at 10 weeks (*p ≤ 0.05 vs. 0 weeks; all time points in the MaioRegen 
group).  
Aggrecan 
In the OAT group, gene expression of aggrecan increased up to a peak at 8 weeks 
and dropped thereafter. In the MaioRegen group, the expression of aggrecan instead 
continuously decreased to minimal levels at 8 weeks and 10 weeks . 
COMP  
While there was no COMP expression in the OAT group at any time, decreasing COMP 
expression was detected in the MaioRegen group at 0 and 8 weeks only. 
Collagen 2/1 ratio 
Due to the lack of collagen 1 expression at 0, 8, and 10 weeks, the collagen 2/1 ration 
was not informative for the OAT group. The MaioRegen group showed a consistent, 
significant increase until 10 weeks, with peak-values more than 2000-fold higher than 
those at 0 weeks. 
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Aggrecan/Collagen 1 ratio 
As for the collagen 2/1 ratio, the aggrecan/collagen 1 in the OAT group was not 
informative. In the MaioRegen group, in contrast, this ratio showed 2.5-fold maxima at 
4 weeks and 10 weeks (Fig. 11).  
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Figure 11: Cartilage ring; relative gene expression (ΔΔ Ct) of Collagen 1, Collagen 2, Aggrecan, and COMP in 
OAT and MaioRegen cultures (each n= 3) after 0, 4, 8 and 10 weeks. *p ≤ 0.05 vs. 0 weeks, +p ≤ 0.05 vs. 4 weeks, 
# p ≤ 0.05 vs. 8 weeks. 
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5.2.2 Cartilage ring (lysis buffer) 
Collagen 1 
Collagen 1 expression in the OAT group showed a transient peak at 
4 and 8 weeks. In the MaioRegen group, collagen 1 expression was 
not detected at any time point (Fig. 12).  
Collagen 2 
In the OAT group, the expression of collagen 2 showed a constant level with a temporal 
maximum at 8 weeks.  However, in the MaioRegen group the expression of collagen 
2 continuously increased over time, reaching values 30-fold above baseline at 10 
weeks (in analogy to the 100-fold increase over time in the corresponding cartilage 
rings; see Fig. 11). 
Aggrecan 
Aggrecan expression in the OAT group showed a maximum at 8 and 10 weeks, and 
also the aggrecan expression in the MaioRegen group continuously increased until 10 
weeks (in parallel to the intense aggrecan signals at the surface of the cartilage ring 
and at the interface between the cartilage ring and the cartilaginous part of the 
MaioRegen scaffold; see Figure 9).  
COMP 
There was no expression of COMP in the OAT group. In the MaioRegen group, COMP 
expression increased to a peak at 8 and 10 weeks. 
Collagen 2/1 ratio 
In the OAT group, this ratio showed a decrease to very low values over time. As there 
was no collagen 1 expression in the MaioRegen group, this ratio was not informative. 
Aggrecan/ Collagen 1 
In the OAT group, this ratio continuously increased to a peak at 10 weeks. As explained 
above, this ratio was not informative for the MaioRegen group.  
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Figure 12: Cartilage ring (lysis buffer); relative gene expression (ΔΔ Ct) of Collagen 1, Collagen 2, Aggrecan, 
and COMP in OAT and MaioRegen cultures (each n= 3) after 0, 4, 8 and 10 weeks. *p ≤ 0.05 vs. 0 weeks, +p ≤ 
0.05 vs. 4 weeks, # p ≤ 0.05 vs. 8 weeks.  
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5.2.3 Bone ring 
Collagen 1 
In the OAT group, the gene expression of collagen 1 stayed at a 
plateau level until 4 weeks and then fell to non-detectable expression 
levels at 10 weeks. In the MaioRegen group, a significant peak was 
observed at 4 weeks (20-fold increase), which successively decreased to non-
detectable values at 10 weeks.  
Collagen 2 
In the OAT group, collagen 2 expression showed a stepwise decrease to very low 
levels at 10 weeks. In the MaioRegen group, in contrast, collagen 2 expression showed 
a relative maximum after 4 weeks and thereafter returned to baseline levels. 
Aggrecan 
The expression of aggrecan in the OAT group continuously decreased to undetectable 
levels at 10 weeks. In the MaioRegen group, aggrecan expression showed a 2-fold 
increase until week 8 (in analogy to the increased aggrecan deposition observed in 
histology; Fig. 9). 
COMP 
In the OAT group, COMP was not detected at any time point. In the MaioRegen group, 
COMP expression increased 2-fold until 4 weeks and dropped thereafter. 
Collagen 2/1 ratio 
This ratio decreased to approx. ½ over time in the OAT group. In the MaioRegen group, 
this ratio showed a minimum at 4 and 8 weeks and returned to base line levels at 10 
weeks. 
Aggrecan/ Collagen 1 
In the OAT group, this ratio remained nearly constant with a transient minimum after 4 
weeks. In the MaioRegen group, this ratio drastically decreased beginning at 4 weeks 
to values much beneath baseline level.  
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Figure 13: Bone ring; relative gene expression (ΔΔ Ct) of Collagen 1, Collagen 2, Aggrecan, and COMP in OAT 
and MaioRegen cultures (each n= 3) after 0, 4, 8 and 10 weeks. *p ≤ 0.05 vs. 0 weeks, +p ≤ 0.05 vs. 4 weeks, # p 
≤ 0.05 vs. 8 weeks.  
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5.2.4 Bone ring (lysis buffer) 
Collagen 1 
While in the OAT group the expression of collagen 1 decreased from 
base line levels at 0 and 4 weeks to almost undetectable at 10 weeks, 
collagen 1 expression in the MaioRegen group rose to a 3-fold peak 
after 4 weeks and returned to baseline thereafter (Fig. 14; in both cases similar to the 
findings in the bone ring; see Fig. 13). 
Collagen 2 
Collagen 2 expression in the OAT group rose to a transient peak at 4 and 8 weeks and 
thereafter returned to baseline (similar to the bone ring; see Fig 13). In the MaioRegen 
group, there was no collagen 2 expression at any time point. 
Aggrecan 
Aggrecan expression showed a 400-fold peak at 4 weeks and a subsequent decline to 
baseline in the OAT group. In the MaioRegen group, there was again no mRNA 
expression. 
COMP 
There was no COMP expression in either the OAT or in the MaioRegen group. 
Collagen 2/ 1 ratio 
In the OAT group, this ratio steadily increased over time with a 3.5-fold maximum at 
10 weeks. In the MaioRegen group, this ratio was not informative. 
Aggrecan/ Collagen 1 ratio 
In the OAT group, this ratio showed a 300-fold peak at 4 weeks and a subsequent 
decrease to values 200-fold above baseline. In the MaioRegen group, this ratio was 
again not informative. 
  
46  
 
 
t in weeks 
OAT MaioRegen 
R
el
. g
en
e 
ex
p
r.
(Δ
Δ
 C
t)
 
C
o
lla
ge
n
 1
 
 
 
C
o
lla
ge
n
 2
 
  
A
gg
re
ca
n
 
  
C
O
M
P
 
  
C
o
lla
ge
n
 2
/1
 
  
A
gg
re
ca
n
/ 
C
o
l 1
 
  
Figure 14: Bone ring (lysis buffer); relative gene expression (ΔΔ Ct) of Collagen 1, Collagen 2, Aggrecan, and 
COMP in OAT and MaioRegen cultures (each n= 3) after 0, 4, 8 and 10 weeks. *p ≤ 0.05 vs. 0 weeks, +p ≤ 0.05 
vs. 4 weeks, # p ≤ 0.05 vs. 8 weeks.  
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5.2.5 Implant cartilaginous part 
Collagen 1 
In the OAT group, collagen mRNA showed a peak at 4 weeks and 
then decreased to a plateau above baseline levels.  In the MaioRegen 
group, no collagen 1 expression was measured (Fig. 15). 
Collagen 2 
Collagen 2 expression was only detected at 8 weeks in the OAT group, but not in the 
MaioRegen group. 
Aggrecan 
Progressively increasing aggrecan expression was measured in the OAT group (20-
fold above base-line at 10 weeks), while no expression was detected in the MaioRegen 
group. 
COMP 
COMP expression was not detected in either the OAT or in the MaioRegen group. 
Collagen 2/ 1 ratio 
In the OAT group, this ratio showed a peak value after 8 weeks. For the MaioRegen 
group, this ratio was not informative. 
Aggrecan/ Collagen 1 ratio 
In the OAT group, this ratio showed a continuous increase over time (Fig. 15; in 
analogy to the findings in the cartilage lysis buffer; see Fig 12). For the MaioRegen 
group, this ratio was again not informative. 
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Figure 15: Implant cartilaginous part; relative gene expression (ΔΔ Ct) of Collagen 1, Collagen 2, Aggrecan, 
and COMP in OAT and MaioRegen cultures (each n= 3) after 0, 4, 8 and 10 weeks. *p ≤ 0.05 vs. 0 weeks, +p ≤ 
0.05 vs. 4 weeks, # p ≤ 0.05 vs. 8 weeks.  
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5.2.6 Implant osseous part 
Collagen 1 
The collagen 1 expression in the OAT group stayed at baseline levels 
throughout culture. In the MaioRegen group, expression showed a 
transient peak-value at 8 weeks (7.5-fold) and then decreased again 
(Fig. 16). 
Collagen 2  
The expression of collagen 2 in the OAT group showed a significant peak at 4 weeks 
(4-fold), followed by a decrease to expression values below baseline. In the 
MaioRegen group, the curve of collagen 2 expression peaked at 8 weeks with a more 
than 20-fold increase and thereafter decreased to levels above baseline.  
Aggrecan 
In the OAT group, aggrecan was expressed at constant levels with a transient 
maximum after 4 weeks (comparable to the collagen 2 expression). In the MaioRegen 
group, there was an increase of the aggrecan expression at 8 weeks and a subsequent 
return to baseline levels thereafter (comparable to the collagen 2 expression, but also 
to the collagen 1 expression). 
COMP 
There was no COMP expression in either the OAT group or the MaioRegen group. 
Collagen 2/ 1 ratio 
In the OAT group, this ratio showed a significant peak at 4 weeks, followed by a 
continuous decrease to values below baseline at 10 weeks. A similar peak was 
detected in the MaioRegen group at 8 weeks. 
Aggrecan/ Collagen 1 ratio 
In the OAT group, this ratio showed a significant maximum at 4 weeks, whereas the 
maximum in the MaioRegen group is reached at 8 weeks (Fig. 16). 
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Figure 16: Implant osseous part; relative gene expression (ΔΔ Ct) of Collagen 1, Collagen 2, Aggrecan, and 
COMP in OAT and MaioRegen cultures (each n= 3) after 0, 4, 8 and 10 weeks. *p ≤ 0.05 vs. 0 weeks, +p ≤ 0.05 
vs. 4 weeks, # p ≤ 0.05 vs. 8 weeks.  
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5.3 DMB Assay 
For the DMB assay, the individual components of the osteochondral model [i.e., bone 
ring (and its lysis buffer preparation), cartilage ring, implant cartilaginous part, and 
implant osseous part] were subjected to separate measurements of their 
glycosaminoglycan (GAG) containment. 
Cartilage Ring 
In the cartilage rings of the OAT group, the content of GAG was largely constant over 
time (approx. 12 mg/g), with a minor peak after 8 weeks (19.7 mg/g). In the MaioRegen 
group, the GAG concentration was maintained at overall constant values (approx. 
12.5 mg/g) with a transient minimum at 4 weeks. 
Bone rings 
In both the OAT and the MaioRegen group, the GAG concentration was almost 
constant over the whole culture period (approx. 24 mg/g). 
Bone lysis buffer 
In the OAT group, the concentration of GAGs increased steadily over time with a 
maximum at 10 weeks (8.6 mg/g). In the MaioRegen group, a maximum was measured 
after 4 weeks (8.5 mg/g), followed by concentrations above baseline.  
Implant cartilaginous part 
In the OAT group, there was a decrease in the GAG content detected over time (from 
33.9 mg/g at 0 weeks; to10.1.mg/g at 10 weeks). In the MaioRegen group, however, 
constant values were observed (approx. 22 mg/g). 
Implant osseous part 
In the OAT group, increasing concentrations were observed with a peak at 8 weeks 
(max. 41.9 mg/g), that decreased thereafter (16.1 mg/g).  In the MaioRegen group, 
GAG concentrations remained almost constant (approx. 17 mg/g).  
There was no significant difference between OAT and MaioRegen for the GAG content 
in any component of the osteochondral model. 
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Figure 17: Shown are the GAG concentrations of either the OAT or the MaioRegen group over time (0, 4, 8, 10 
wk) in mg/g. Data are presented as mean value ± SEM. *p ≤ 0.05 vs. 0 weeks, +p ≤ 0.05 vs. 4 weeks. 
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5.4 ELISA of the cell culture supernatants 
Collagen 1: In the OAT group, the release of collagen 1 into the supernatants increased 
slightly during the first 4 weeks (from 13.0 µg/ml to 15.6 µg/ ml) and decreased in the 
time after to values below baseline (10.1µg/ml and 9.8 µg/ ml). In the MaioRegen 
group, there were different kinetics, with an increasing collagen 1 being release until 
8 weeks (12.2 µg/ml) and a subsequent decrease (9.1 µg/ ml).   
Collagen 2: In both the OAT and MaioRegen group, the concentrations of released 
collagen 2 remained constant with exception to a transient and significant minimum at 
8 weeks (OAT: 109.7 µg/ml and MaioRegen: 71.0 µg/ml).  
Aggrecan: In both groups, the aggrecan release into the supernatants showed 
constant values over time (approx. 60 ng/ml for OAT and MaioRegen). 
  t in weeks 
Collagen 1 Collagen 2 Aggrecan 
Q
u
an
ti
ty
  (
µ
g
/m
l (C
o
l1
, 2
) r
es
p
. n
g
/m
l (A
G
C
)) 
  
O
A
T 
   
M
ai
o
R
e
ge
n
 
   
Figure 18: Quantification of collagen 1 (µg/ml), collagen 2 (ng/ml) and Aggrecan (ng/ml) concentrations in the 
supernatants of the cell cultures of OAT and MaioRegen®. Values are expressed as mean ± SEM; Standard error 
of the mean. *p ≤ 0.05 vs. 0 weeks, +p ≤ 0.05 vs. 4 weeks.  
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5.5 Biomechanical testing 
Since the measurement of the push-out forces for the extrusion of the OAT implant 
resulted in values above the measurable range, valid measurements can only be 
reported for the MaioRegen group.  
The largest push-out force (0.84 N) was detected at 4 weeks. This force decreased 
over time to very low values (0.23 N at 8 weeks; 0.17 N at 10 weeks).  
 
Figure 19:  The force ΔF necessary to extrude the MaioRegen implant is shown for each time point of in vitro 
culture (0, 4, 8, and 10 weeks). Data are presented as means ± SEM.  
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6 DISCUSSION 
6.1 Suitability of the new model 
In this study, the OAT control implant and the cell-free, collagen-hydroxyapatite 
MaioRegen® scaffold were cultured for 0, 4, 8 and 10 weeks in bovine osteochondral 
cylinders and analyzed with regard to histology, gene expression, as well as 
biochemical and biomechanical features. 
The present study represents the first report on a novel osteochondral model for the in 
vitro testing and analysis of diverse implants with clinical potential for the treatment of 
osteochondral defects. There are a number of advantages of this model:  
1) it is readily available at low cost (slaughter house material); 2) it allows harvesting 
of up to 30 osteochondral cylinders from one bovine knee joint; 3) it is thus suitable for 
(semi) high-throughput studies, e.g. in an industrial setting, since large numbers of 
osteochondral cylinders can be cultured simultaneously with low demand on 
harvesting, handling, and (organ) culture; 4) the harvested osteochondral material 
initially shows intact tissue structures without structural alterations and largely 
maintains this integrity throughout culture for up to 10 weeks (without massive loss of 
proteoglycans or other matrix molecules);  5) it allows multi-technological and highly 
differential analysis for each of the involved tissue and material components of the new 
model.  
All these points can be very challenging, if not impossible, when using human samples 
from patients suffering from osteoarthritis or other joint degenerative diseases. The 
involved tissue types survived 10 weeks of cell culture in this study without any signs 
of necrosis. They showed vital metabolic activity during the whole culture period. This 
observation is strengthened by an overall constant, long-term concentration of 
glycosaminoglycans in each of the tissue components (see Fig. 17). 
On the other hand, some proteoglycan loss over time was observed in the cartilaginous 
parts of the osteochondral cylinder and the OAT control implant, possibly due to the 
well-known detachment of the lamina splendens (Sohn et al. 2002). Nevertheless, no 
clear signs of cartilage de-differentiation were observed either histologically or in gene 
expression analysis, again underlining the high vitality of the present in vitro culture 
model. 
In particular, ‘callus-like’ bone formation around the OAT control implant and 
reintegration of the implant into the “host” osteochondral cylinder emphasized the 
vitality of the system. Similar tendencies were noted in a somewhat less complex 
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model system using exclusively cartilage cylinders (Dunzel et al. 2013). Also, large 
depositions of aggrecan were observed in the primarily cell-free MaioRegen scaffold. 
Thus, the model seems to provide optimal basic conditions to study the complex 
situation of osteochondral defect regeneration. It is therefore suitable for the analysis 
of diverse implants and their particular features, such as cell seeding and/or 
proliferation, matrix deposition, and successful  tissue integration. 
In the present study, the above-mentioned features were monitored using a 
combination of time-dependent surrogate parameters, e.g., structural and molecular 
(immuno) histological features, gene expression development, as well as the time 
course of matrix molecule content in the tissue/implant components and matrix release 
into the supernatant of the culture system. In comparison to previous studies 
investigating in vitro cartilage regeneration (Dunzel et al. 2013, Pretzel et al. 2013, 
Vinardell et al. 2009), the innovations and improvements of the present model are:  
1) the use of an osteochondral host cylinder; 2) the application of a bone graft 
harvesting system well established in the clinical setting (Arthrex); and 3) the 
preparation of defect sizes that mimic the surface area of OATS cylinders in the clinical 
situation (approx. 0.2 cm2). All these features serve to simulate the in vivo situation 
and thus to enhance the transferability to clinically relevant treatment approaches.   
However, the limitations of this study are: 1) the use of bovine instead of human 
material with possible differences in structural, molecular, and biomechanical 
properties (Secretan et al. 2010); 2) the lack of regular blood supply and thus possibly 
insufficient long-term nutrition (Kuo et al. 2006); 3) the lack of biomechanical forces 
acting on the osteochondral cylinder and the implant during culture (Deschner et al. 
2003); and 4) technical problems for the biomechanical testing of the OAT group 
(incarceration of the implant in the host cylinder).  
6.2 Integrity of the osteochondral cylinders 
In the OAT and the MaioRegen group, the cartilage ring of the host cylinder 
demonstrated chondrogenic differentiation during cell culture (Table 6). This is 
demonstrated by the detection of aggrecan in the matrix, aggrecan-positive cells on 
the cartilage surface, as well as increased gene expression for collagen 2 and 
aggrecan (see Fig. 11; Table 7). In addition, the glycosaminoglycan concentration of 
the cartilage ring remained on a stable level in the DMB assay, indicating constant net 
proteoglycan content in the cartilage ring (Fig. 17). 
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This net proteoglycan content of the cartilage ring in culture depends on at least 2 
different and opposing factors. On one hand, there was considerable proteoglycan loss 
from the cartilage matrix, as indicated by a diminished staining in the Safranin-O and 
aggrecan staining and a continuous aggrecan release into the supernatant of both the 
OAT and MaioRegen cultures over the whole incubation period (approx. 60 ng/ml at 
all timepoints). However, an estimation of the proteoglycan content in the cartilage 
(approx. 6% w/w; approx. 3.2 mg in host cylinder and OAT implant) and the quantitative 
proteoglycan release into the culture supernatant (total of 10 ng/day and 560 ng in 8 
weeks) indicated that at most 1-2% of the cartilage proteoglycan was released during 
culture (Muir 1978). 
On the other hand, there were several indications for a local neo-synthesis of 
proteoglycans in the cultured cartilage (Aurich et al. 2005), e.g., aggrecan staining in 
the immediate vicinity of the chondrocytes and a redistribution of aggrecan molecules 
from a cohesive pattern to a multifocal mapping (Sternberg et al. 2013), increased 
collagen 2 and/or aggrecan gene expression in cartilage rings (and its lysis buffer 
preparation) in both implants groups, and a constant net glycosaminoglycan 
concentration in the tissue extracts of the cartilage ring. These findings suggest a vital 
balance of the proteoglycan molecules in the cartilage of the host cylinder and the OAT 
implant, which may also protect the collagen 2 in the cartilage against degradation by 
endogenous proteolytic enzymes (Pratta et al. 2003). 
In comparison to previous studies using pure cartilage rings (Pretzel et al. 2013), there 
was only limited release of collagen 2 into the supernatant (approx. 250 ng/week). The 
likely reason for this difference is that in the present model there is only a very limited 
cartilage area artificially damaged by the preparation process. This is in agreement 
with very limited structural changes of the cartilage components in the current study, 
again supporting the concept of a vital and intact culture system.     
Waldman et. al. showed that mechanical forces acting on the cartilage enhance the 
deposition of extracellular matrix proteins (Waldman et al. 2004). Thus, the lack of the 
mechanical stimulation may have had an impact on matrix deposition and release in 
the present study. As noted above, however, the very limited release of collagen 2 into 
the culture supernatant questions a major influence of the lacking biomechanical 
stimulation on the outcome of the experiments in the current study. In addition, a 
substantial increase of collagen 2 gene expression in the cartilage ring (and its lysis 
buffer preparation (Squires et al. 2003)), as well as an overall lack of fibroblastic 
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dedifferentiation (Tables 6 and 7) does not support a relevant influence of the missing 
biomechanical stimulation in the present study. 
Table 6: Summary of principal histological changes. a) Tissue differentiation  symbolizes a differentiation 
respective the primary tissue type of this site;  indicates a de-differentiation to a tissue other than the primary 
tissue type, for the MaioRegen implant every type of tissue formation was counted as differentiation; b) Cell 
migration into the diverse compartments. - no cell migration, + moderate cell migration, ++ strong cell migration. 
*Cartilage/bone surface represents the histological equivalent to the term cartilage/bone lysis buffer used above; 
MR = MaioRegen 
In analogy to the cartilage rings, the bone rings showed a similar behavior in the OAT 
and the MaioRegen group. Thus, the bone rings showed an extreme high vitality, which 
is based on the following features: 1) no histological observed necrosis or tissue 
degradation; 2) an almost complete closure of the osseous gap in the case of the OAT 
group and a substantial bone regeneration at the edge of the bone ring around the 
MaioRegen implant (Fig. 7); and 3) a transient decrease of the collagen 2/1 and 
aggrecan/ collagen 1 ratios (indicating conserved bone differentiation over time; Tables 
6 and 7). In addition, proteoglycan deposition into the bone ring was observed 
histologically, with one focus on the immediate vicinity of the implant (Fig. 8).  In 
combination with the above mentioned decrease of the gene expression ratios, this 
may reflect the attempt of the bone to regenerate via callus-like, enchondral tissue 
formation, most likely in response to the artificial fracture/trauma set by the harvesting 
technique (Cvetkovic et al. 2015). Further evidence for this hypothesis is provided by 
the collagen 2 and aggrecan gene expression kinetics with an initial increase and a 
late decrease (Fig. 13), as this is typical for long term enchondral ossification through 
primary de-differentiation with subsequent bone differentiation (Bucholz 2002, Park et 
al. 2015). 
Furthermore substantial and overall constant collagen 1 release into the culture 
supernatants was detected (Fig. 18), while collagen 1 expression showed to be 
decreasing over time in the both the OAT and the MaioRegen group. Considering the 
histological intactness of the bone ring, release and limited neo synthesis are of minor 
Tissue 
Cartilage 
ring 
Bone ring 
Implant 
cartilaginous 
part 
Implant 
osseous part 
Cartilage 
surface* 
Bone 
surface* 
OAT MR OAT MR OAT MR OAT MR OAT MR OAT MR 
Tissue 
differentiation  
          
  
Cell migration + + ++ + + - + ++ + ++ - ++ 
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importance for the integrity of the bone rings, as the other above-mentioned processes 
are predominant this tissues vitality and integrity. 
6.3 Matrix formation of the implants 
In the cartilaginous part of the OAT implant, no structural major changes, i.e. massive 
tissue degradation, tissue de-differentiation, or gap closure between implant and ring, 
were observed. The latter as an expression of insufficient regeneration capacity is a 
well-known phenomenon of cartilage due to its complex structure and bradytrophic 
nutrition (Siebert et al. 2001, Obradovic et al. 2001). 
In analogy to the situation in the bone ring, the osseous part of the implant showed 
large proteoglycan depositions starting at 4 weeks of culture (Fig. 8) that resulted in 
increasing glycosaminoglycan contents. In addition, gene expression of collagen 1, 2 
and aggrecan initially increased and decreased thereafter (Fig. 16). This again, 
supported by overall decreasing collagen 2/1 and aggrecan/collagen 1 ratios, supports 
the hypothesis of callus-like tissue formation in this osteochondral model (Schnabel et 
al. 2002) and gives evidence for cross-talk between the implant and its “host” 
osteochondral cylinder. Similar observations regarding gap closure and cross-talk 
were made in animal models as well as in the clinical setting (Woelfle et al. 2013, 
Richter et al. 2015, Siebert et al. 2001). 
In comparison to the bone ring, in the osseous part of the implant nutrients have to 
diffuse over longer distances, therefore metabolism may show somewhat different 
kinetics (Burke und Kelly 2012). In this study, this accounts for large proteoglycan 
depositions, which are more intense and cohesive in the implant than in the bone ring 
of both the OAT and the MaioRegen group. This suggests not only a high vitality of this 
tissue but also massive matrix formation in the implant.  
In the collagen-enriched top lay of the MaioRegen scaffold no cell migration was 
observed, rather degradation and dissolution dominated this structure. This is in 
contrast to experimental in vivo studies that were carried out previously (Kon et al. 
2010). Considering the impressive density of this layer may reason for its 
impermeability for cell migration (Pretzel et al. 2013). The dissolution of this layer is 
most likely caused by both, its solubility and its weak attachment to the underlying 
layer. Thus, large flakes shifted off during culture. Yet it remains questionable if joints 
treated with MaioRegen scaffolds that were arthroscopically examined in a second look 
biopsy showed to be very soft because the top layer had dissolved (Brix et al. 2016). 
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Table 7: Comparison of diverse gene expression patterns across tissues and groups. Indicated are the overall 
tendencies over time of (de-)differentiation ratios (Collagen 2/1 and AGC/ Col 1). Generally, in cartilaginous tissue 
increasing ratios signify differentiation, while the opposite is true in osseous tissue. 
In contrast, the lower and hydroxyapatite containing layer of the MaioRegen scaffold 
showed to be an attractive location for cell migration. Histologically large aggrecan and 
proteoglycan depositions were detected in this layer. In addition, gene expression for 
collagen 1, 2 and aggrecan showed a peak after 8 weeks. This late maximum is most 
likely caused by an initial de-differentiation and subsequent re-differentiation of the 
mRNA expression in cells that had migrated into the scaffold – a phenomenon well-
known from monolayer cell culture that is eventually transferred into a 3D culture 
(Darling und Athanasiou 2005, Kaps et al. 2004). 
Comparing the metabolic activities of this layer to the one of the osseous part of the 
OAT, it seems likely that callus-like tissue formation and enchondral ossification at an 
early stage is taking place here as well (Christensen et al. 2015, Filardo et al. 2013). 
Although the MaioRegen scaffold dissolved and the gap between implant and “host” 
osteochondral cylinder enlarged, cross-talk was observed as the bone ring showed 
bone formation on the edge neighboring the implant.  
Furthermore, in pure chondral in vitro models it often has been shown that 
chondrocytes are the responsible cell type for the measured gene expression in 
scaffolds (Pretzel et al. 2013). However, in the present model, several tissue 
components may be the origin of cell emigration, thus diverse cell types may emigrate. 
In both the OAT and the MaioRegen group, cells that had emigrated onto the cartilage 
showed cartilage-like gene expression patterns (Fig. 12). Cells that emigrated onto the 
bone ring showed cartilaginous gene expression patterns as well in the OAT group. 
However, in the MaioRegen group only collagen 1 gene expression was detected (Fig. 
14). Thus, it can be hypothesized that 1) through cross-talk MaioRegen may limit the 
emigration of cartilaginous cells onto the bone or 2) that it enhances the 
 
OAT MaioRegen 
 
Collagen 2/1 AGC/ Col 1 Collagen 2/1 AGC/ Col 1 
Cartilage rings ↑ ↑ ↑  ↑  
Cartilage (rings) lysis buffer ↓  ↑  ↑ ↑ 
Bone rings ↓  ↓  ↓ ↓  
Bone (rings) lysis buffer ↑  ↑  ↓ ↓ 
Implant cartilaginous part ↑  ↑  - - 
Implant osseous part ↓  ↓ ↑  ↑  
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emigration/differentiation of cells with fibrous origin or capacity (Vinardell et al. 2009, 
Im 2015). However, this specific detail can be answered only partially by the analysis 
of the cartilage and/or bone lysis buffer and may therefore be subject of further 
research. 
Although the osseous part of the scaffold is capable of stabilizing cells of a 
fibrocartilaginous phenotype, there is no evidence for a lateral bonding with 
biomechanical impact at any time, which is explained by histological evidence for the 
scaffold’s dissolution. Thus, decreasing resistances in biomechanical testing and 
questionable clinical results of the MaioRegen implant can be reasoned on a molecular 
level (Brix et al. 2016, Christensen et al. 2015). 
6.4 Tenor of this study and prospects for the clinical use 
This study is of great interest as it: 1) showed a novel, stable osteochondral culture 
system; 2) identified structural and molecular reactions of the analyzed tissue 
components (differentiating vs. de-differentiating processes, matrix deposition, cell 
migration, tissue integration; Tables 6 and 7); 3) found reasons for the impaired clinical 
performance of the MaioRegen scaffold on a molecular level and 3) demonstrated high 
tissue-integrative properties of OATs.  
Clinical efforts to repair damaged articular cartilage currently face major obstacles due 
to limited intrinsic repair capacity of the tissue and unsuccessful biological 
interventions. This shows the need for better therapeutic strategies (Caldwell und 
Wang 2015). In the present in vitro model, the gold standard for osteochondral repair, 
which is the OAT, proved highly suitable for osseous regeneration (Kadakia und 
Espinosa 2013).  
The cell-free MaioRegen scaffold showed tissue-adapting properties such as cell 
migration, extracellular protein deposition, and biocompatibility without any signs of 
toxicity. These findings are in accordance with previously gathered in vivo data (Kon 
et al. 2009, Kon et al. 2010). However, recent clinical studies noted similar critical 
points of this scaffold such as poor osteochondral integration, alleged partial 
dissolution and a somewhat weak lateral bonding capacity (Brix et al. 2016). As these 
clinical findings can be strengthened by the presented experimental in vitro data, 
further research has to be initiated in order to assess the general clinical applicability 
of this construct.  
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7 CONCLUSION 
The described model is suitable for the in-vitro investigation of osteochondral defects 
and their appropriate treatment via natural transplants or specifically tissue-engineered 
implants. In addition, it has a quasi-unlimited availability and is of reproducible quality. 
Furthermore, it is cost-effective and provides a broad spectrum of molecular and 
mechanical techniques for consecutive analysis. Consequently, large data contribute 
to the comprehension of this complex system, which is crucial for the final assessment 
of the implant being investigated. 
In the present study, the osteochondral integrative abilities of the MaioRegen® scaffold 
and the osteochondral healing responses of OATs were compared. In both groups, 
cross-talk between the implant and the osteochondral rings were observed, indicating 
vigorous processes in the system. 
In this study, the clinically widely established OAT technique proofed its osteochondral 
healing response on a bio-structural level. Therefore, this group could be considered 
as a to-be-established standardized control group for future studies in this setting. This 
is of interest, as pre-clinical, standardized in vitro testing will be of increasing 
importance for future product licensing (European Medicines Agency 2009).  
In contrast to the OAT, the MaioRegen scaffold’s structural long-term stability has to 
be questioned, as it histologically seemed to lose its density, dissolving in the course 
of the experiment. Therefore, with respect to recent clinical data (Christensen et al. 
2015, Brix et al. 2016), the scaffold has not only to be used with caution in the clinical 
context but also has to be object to further studies because different clinical studies 
found contrary results (Berruto et al. 2014, Filardo et al. 2013, Kon et al. 2012). 
This demonstrates the demand for further research concerning MaioRegen in 
particular and osteochondral regeneration in general, which is of common interest for 
the individually affected patient and the contributors of the health care system.  
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